
Opinion|Videos|July 9, 2024
Examining Challenges with Drug Switching and Step Therapy in MS Treatment
Key opinion leaders discuss the challenges associated with step therapy requirements after initially selecting a drug class, the patient factors considered when deciding to switch a patient with non-relapsing secondary progressive multiple sclerosis to a different therapy, and whether payers commonly employ step therapy between different drug classes.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Do you ever encounter challenges with step therapy requirements after initially selecting a drug class?
- What patient factors do you consider when deciding to switch a patient to a different therapy in patients diagnosed with non-relapsing secondary progressive multiple sclerosis?
- Are step therapies typically used for drugs within the same class, or do payers typically use step therapy between different classes of drugs?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
3
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
4
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
5

















































